ATHA

Athira Pharma Inc

Sep 17 • 10:15AM ET

0.3796

-0.0021 -0.56 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB SAVA AVXL SAGE QURE PRTA INVA AUPH NBIX ANVS

Index	-	P/E	-	EPS (ttm)	-1.54	Insider Own	14.24%	Shs Outstand	39.44M	Perf Week	-0.38%
Market Cap	14.97M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-0.99%	Shs Float	33.82M	Perf Month	-3.40%
Enterprise Value	-13.83M	PEG	-	EPS next Q	-0.11	Inst Own	44.61%	Short Float	2.49%	Perf Quarter	17.91%
Income	-59.85M	P/S	-	EPS this Y	75.40%	Inst Trans	-0.16%	Short Ratio	4.23	Perf Half Y	14.77%
Sales	0.00M	P/B	0.47	EPS next Y	14.52%	ROA	-81.54%	Short Interest	0.84M	Perf YTD	-35.31%
Book/sh	0.81	P/C	0.50	EPS next 5Y	77.17%	ROE	-103.80%	52W High	0.83 -54.07%	Perf Year	-28.13%
Cash/sh	0.76	P/FCF	-	EPS past 3/5Y	-19.25% -73.94%	ROIC	-183.80%	52W Low	0.22 72.88%	Perf 3Y	-89.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.36% 6.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	47.99%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.81	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.88	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.81	EPS Q/Q	74.54%	SMA20	-2.50%	Beta	3.01	Target Price	0.50
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-4.53%	Rel Volume	1.23	Prev Close	0.38
Employees	26	LT Debt/Eq	0.02	Earnings	Aug 07 AMC	SMA200	-4.19%	Avg Volume	199.38K	Price	0.38
IPO	Sep 18, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.42% -	Trades		Volume	38,990	Change	-0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral	$5 → $0.50
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy	$22
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30
Oct-13-20	Initiated	Goldman	Buy	$53

Show Previous Ratings

Sep-11-25 09:00AM	Athira Pharma Announces Reverse Stock Split (GlobeNewswire)
Aug-14-25 07:00AM	Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 (GlobeNewswire)
Aug-07-25 04:05PM	Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +5.95%
May-14-25 11:10AM	Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 (TipRanks) -7.25%
May-13-25 11:00AM	Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit (GlobeNewswire)
04:05PM	Loading…
May-09-25 04:05PM	Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.17%
Feb-27-25 04:05PM	Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Dec-06-24 05:30PM	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-08-24 04:50AM	Athira exploring strategic alternatives after Alzheimers failure (BioPharma Dive) -12.01%
Nov-07-24 04:05PM	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire) +7.14%
Oct-22-24 07:00AM	Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting (GlobeNewswire) +15.73%
Sep-17-24 09:00AM	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Sep-04-24 11:40AM	Alzheimers Trial Failure Sends Athira Stock Down 75% (Barrons.com) -78.43%
11:33AM	Athiras stock topples after Alzheimers drug flops in Phase II/III trial (Pharmaceutical Technology)
08:48AM	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks (Benzinga)
04:01PM	Loading…
Sep-03-24 04:01PM	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) -8.41%
Aug-23-24 09:40AM	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? (Zacks) +6.75%
Aug-07-24 09:40AM	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-01-24 04:05PM	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Jul-31-24 08:05AM	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
Jul-10-24 08:51AM	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up (Zacks)
Jul-09-24 07:00AM	Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) +29.39%
Jun-12-24 07:00AM	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients (GlobeNewswire)
Jun-11-24 07:00AM	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
May-29-24 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace) +22.62%
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
07:00AM	Loading…
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33% +6.47%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +5.00%
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21% -7.26%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)
Nov-29-22 11:00AM	Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimers Disease Patients from ACT-AD Phase 2 Study at CTAD Conference (GlobeNewswire)
Nov-28-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -5.02%
Nov-21-22 07:00AM	Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Nov-16-22 07:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference (GlobeNewswire)
Nov-10-22 04:05PM	Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire) +7.97% +8.39%
Nov-09-22 07:00AM	Athira Pharma to Present at Stifel 2022 Healthcare Conference (GlobeNewswire) -7.07%
Nov-07-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference (GlobeNewswire)
Oct-30-22 08:29AM	Athira Pharma, Inc. (NASDAQ:ATHA) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Oct-17-22 07:00AM	Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients Following Independent, Unblinded Interim Analysis (GlobeNewswire) +9.03%
Sep-16-22 08:14AM	Multiple insiders bought Athira Pharma, Inc. (NASDAQ:ATHA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-06-22 03:22PM	Athira Outlines Possible Comeback For Alzheimer's Candidate (Benzinga)
07:00AM	Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients (GlobeNewswire)
Aug-20-22 08:01AM	Athira Pharma (NASDAQ:ATHA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 04:05PM	Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire)
Aug-03-22 11:28AM	Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients at the Alzheimer's Association International Conference 2022 (GlobeNewswire)

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jun 30 '25	Option Exercise	0.00	36,666	0	177,427	Jul 02 04:35 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jul 01 '25	Sale	0.29	8,526	2,502	168,901	Jul 02 04:35 PM
Litton Mark James	President and CEO	Jun 30 '25	Option Exercise	0.00	108,334	0	350,925	Jul 02 04:34 PM
Litton Mark James	President and CEO	Jul 01 '25	Sale	0.29	25,123	7,374	325,802	Jul 02 04:34 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jun 30 '25	Option Exercise	0.00	46,666	0	82,507	Jul 02 04:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	0.29	10,842	3,182	71,665	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jun 30 '25	Option Exercise	0.00	36,666	0	120,401	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jul 01 '25	Sale	0.29	8,526	2,502	111,875	Jul 02 04:33 PM
Renninger Robert	SVP, Finance and Accounting	Jun 30 '25	Option Exercise	0.00	12,359	0	112,083	Jul 02 04:32 PM
Renninger Robert	SVP, Finance and Accounting	Jul 01 '25	Sale	0.29	2,897	850	109,186	Jul 02 04:32 PM
Mark James Litton	Officer	Jul 01 '25	Proposed Sale	0.29	25,123	7,374		Jul 01 07:37 PM
Javier San Martin	Officer	Jul 01 '25	Proposed Sale	0.29	10,842	3,182		Jul 01 07:36 PM
Kevin Church	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:34 PM
Mark Worthington	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Dec 31 '24	Option Exercise	0.00	46,667	0	46,667	Jan 03 05:05 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jan 02 '25	Sale	0.56	10,826	6,083	35,841	Jan 03 05:05 PM
Litton Mark James	President and CEO	Dec 31 '24	Option Exercise	0.00	108,333	0	267,698	Jan 03 05:04 PM
Litton Mark James	President and CEO	Jan 02 '25	Sale	0.56	25,107	14,108	242,591	Jan 03 05:04 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Dec 31 '24	Option Exercise	0.00	36,667	0	139,271	Jan 03 05:03 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jan 02 '25	Sale	0.56	8,510	4,782	130,761	Jan 03 05:03 PM
Renninger Robert	VP of Finance	Dec 31 '24	Option Exercise	0.00	12,359	0	92,605	Jan 03 05:01 PM
Renninger Robert	VP of Finance	Jan 02 '25	Sale	0.56	2,881	1,619	89,724	Jan 03 05:01 PM
Worthington Mark	General Counsel and CCO	Dec 31 '24	Option Exercise	0.00	36,667	0	92,245	Jan 03 05:00 PM
Worthington Mark	General Counsel and CCO	Jan 02 '25	Sale	0.56	8,510	4,782	83,735	Jan 03 05:00 PM
Javier San Martin	Officer	Jan 02 '25	Proposed Sale	0.56	10,826	6,083		Jan 02 08:06 PM
Mark James Litton	Officer	Jan 02 '25	Proposed Sale	0.56	25,107	14,108		Jan 02 08:05 PM
Mark Worthington	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:04 PM
Kevin Church	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHA

Athira Pharma Inc

Upgrade your FINVIZ experience